Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-10-09Clinical Trial Update: A Study of LY3337641 in Rheumatoid Arthritis [Phase 2]
Phase 2 study of LY3337641 in rheumatoid arthritis was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2019-10-09Clinical Trial Update: TOLERA: Tolerance Enhancement in RA [Phase 2]
Phase 2 clinical trial update for TOLERA aiming at tolerance enhancement in rheumatoid arthritis; status not specified.
-
FDA approval · 2019-10-08FDA Approved: OLUMIANT — Supplemental Application (Eli Lilly and Company)
FDA approves Eli Lilly's supplemental application for OLUMIANT (baricitinib). This action updates the labeling to reflect expanded indicatio…
-
CLINICAL_TRIALS trial_result · 2019-10-07Clinical Trial Update: A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate [Phase 3]
Phase 3 trial comparing Upadacitinib (ABT-494) to placebo and to adalimumab in adults with rheumatoid arthritis inadequately responsive to m…
-
CLINICAL_TRIALS trial_result · 2019-10-07Clinical Trial Update: A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) [Phase 3]
Phase 3 trial comparing upadacitinib monotherapy to methotrexate in adults with rheumatoid arthritis inadequately responding to MTX, complet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-10-07Clinical Trial Update: A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone [Phase 3]
Phase 3 trial comparing upadacitinib to placebo in adults with rheumatoid arthritis on csDMARDs who had an inadequate response, results post…
-
CLINICAL_TRIALS trial_result · 2019-10-07Clinical Trial Update: A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs [Phase 3]
Phase 3 trial comparing upadacitinib to placebo in adults with rheumatoid arthritis who had an inadequate response or intolerance to biologi…
-
FDA approval · 2019-10-07FDA Approved: PIROXICAM — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for piroxicam by Micro Labs Limited, adding or updating a generic piroxicam product.
-
CLINICAL_TRIALS trial_result · 2019-10-04Clinical Trial Update: A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate [Phase 3]
Phase 3 trial comparing upadacitinib monotherapy to methotrexate monotherapy in adults with rheumatoid arthritis; study completed with resul…
-
CLINICAL_TRIALS trial_result · 2019-10-04Clinical Trial Update: A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone [Phase 2]
Phase 2 trial assessing the efficacy and safety of upadacitinib with methotrexate in adults with rheumatoid arthritis who had an inadequate …
-
CLINICAL_TRIALS trial_result · 2019-10-01Clinical Trial Update: Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis [Phase 4]
A Phase 4 clinical trial comparing combination disease-modifying antirheumatic drugs with methotrexate therapy in early rheumatoid arthritis…
-
FDA approval · 2019-09-24FDA Approved: SIMPONI — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for SIMPONI (golimumab) submitted by Janssen Biotech, Inc. The approval updates the drug's label…
-
CLINICAL_TRIALS trial_result · 2019-09-16Clinical Trial Update: A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis [Phase 1]
A Phase 1b study of MEDI4920 in adults with rheumatoid arthritis has completed, and the results were posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-09-13Clinical Trial Update: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
A completed real-world outcome study evaluating adalimumab in Chinese patients with rheumatoid arthritis, with results posted in 2019.
-
FDA approval · 2019-09-11FDA Approved: OXAPROZIN — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Oxaprozin from Dr. Reddy's Laboratories Limited, updating the existing approval for this generic…
-
CLINICAL_TRIALS trial_result · 2019-09-10Clinical Trial Update: Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) [Phase 2]
Phase 2 trial evaluating GDC-0853 versus placebo and adalimumab in rheumatoid arthritis; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2019-09-09Clinical Trial Update: Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis [Phase 2]
Phase 2 trial updates the evaluation of low-dose recombinant human IL-2 for rheumatoid arthritis, with results posted after completion.
-
CLINICAL_TRIALS trial_result · 2019-09-09Clinical Trial Update: Very Early Versus Delayed Etanercept in Patients With RA [Phase 4]
Phase 4 trial comparing very early versus delayed initiation of etanercept in rheumatoid arthritis has completed.
-
FDA approval · 2019-08-30FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc, marking an approved modif…
-
FDA approval · 2019-08-30FDA Approved: RELAFEN DS — Original Application (Carwin Pharmaceutical Associates, LLC)
FDA approval of RELAFEN DS (nabumetone) through an original generic application by Carwin Pharmaceutical Associates, expanding access to thi…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab [Phase 3]
Phase 3 trial comparing ABP710 to infliximab in moderate to severe rheumatoid arthritis has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Effects of a Rheumatoid Arthritis Self-management Program [NA]
The document provides a trial update on a rheumatoid arthritis self-management program. It notes that the study has completed and results we…
-
CLINICAL_TRIALS trial_result · 2019-08-26Clinical Trial Update: Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis [Phase 3]
A Phase 3 study evaluating the biodistribution and detection of radiolabeled anti-TNFα in patients with active rheumatoid arthritis and acti…
-
CLINICAL_TRIALS trial_result · 2019-08-26Clinical Trial Update: Optimal MTX Dose With Folic Acid Randomized Case-control Trial [Phase 4]
Phase 4 randomized case-control trial evaluating the optimal methotrexate dose with folic acid in rheumatoid arthritis.
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis [Phase 2]
Phase 2 dose-range finding study of ALX-0061 combination therapy in rheumatoid arthritis completed; results posted.